SKYE · Skye Bioscience, Inc.
$0.61
-0.01 (-1.45%)
At close · Jul 29
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued. After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed May 11, 2026
Market Cap
$21.61M
Shares
35.14M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Capacity | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-05-10 | $100,000,000 | — | — | — | 10-K , filed 2026-03-10 |